Addition of (131)I-MIBG to PRRT ((90)Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors

Peptide receptor radionuclide therapy (PRRT) is an effective treatment for metastatic neuroendocrine tumors. Delivering a sufficient tumor radiation dose remains challenging because of critical-organ dose limitations. Adding (131)I-metaiodobenzylguanidine ((131)I-MIBG) to PRRT may be advantageous in...

Descripción completa

Detalles Bibliográficos
Autores principales: Bushnell, David L., Bodeker, Kellie L., O’Dorisio, Thomas M., Madsen, Mark T., Menda, Yusuf, Graves, Stephen, Zamba, Gideon K.D., O’Dorisio, M. Sue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2021
Materias:
Theranostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882893/
https://www.ncbi.nlm.nih.gov/pubmed/33517327
http://dx.doi.org/10.2967/jnumed.120.254987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882893/
https://www.ncbi.nlm.nih.gov/pubmed/33517327
http://dx.doi.org/10.2967/jnumed.120.254987

Ejemplares similares